These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 32838169)

  • 1. Systematic and Statistical Review of Coronavirus Disease 19 Treatment Trials.
    Siordia JA; Bernaba M; Yoshino K; Ulhaque A; Kumar S; Bernaba M; Bergin E
    SN Compr Clin Med; 2020; 2(8):1120-1131. PubMed ID: 32838169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of Remdesivir, Lopinavir/Ritonavir, and Favipiravir for COVID-19 Treatment: A Systematic Review.
    Qomara WF; Primanissa DN; Amalia SH; Purwadi FV; Zakiyah N
    Int J Gen Med; 2021; 14():8557-8571. PubMed ID: 34849001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-analysis of arbidol versus lopinavir/ritonavir in the treatment of coronavirus disease 2019.
    Yu M; Wang DC; Li S; Lei YH; Wei J; Huang LY
    J Med Virol; 2022 Apr; 94(4):1513-1522. PubMed ID: 34837230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lopinavir-ritonavir alone or combined with arbidol in the treatment of 73 hospitalized patients with COVID-19: A pilot retrospective study.
    Lan X; Shao C; Zeng X; Wu Z; Xu Y
    Int J Clin Pharmacol Ther; 2021 May; 59(5):378-385. PubMed ID: 33624583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19: The TOGETHER Randomized Clinical Trial.
    Reis G; Moreira Silva EADS; Medeiros Silva DC; Thabane L; Singh G; Park JJH; Forrest JI; Harari O; Quirino Dos Santos CV; Guimarães de Almeida APF; Figueiredo Neto AD; Savassi LCM; Milagres AC; Teixeira MM; Simplicio MIC; Ribeiro LB; Oliveira R; Mills EJ;
    JAMA Netw Open; 2021 Apr; 4(4):e216468. PubMed ID: 33885775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of pharmacological interventions in COVID-19: A network meta-analysis.
    Selvarajan S; Anandaradje A; Shivabasappa S; Melepurakkal Sadanandan D; Nair NS; George M
    Br J Clin Pharmacol; 2022 Sep; 88(9):4080-4091. PubMed ID: 35357033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic interactions between the potential COVID-19 treatment drugs lopinavir/ritonavir and arbidol in rats.
    Hu Y; Zuo M; Wang X; Wang R; Li L; Lu X; Jiang S
    J Zhejiang Univ Sci B; 2021 Jul; 22(7):599-602. PubMed ID: 34269012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic review and Bayesian network meta-analysis for comparative safety assessment of favipiravir interventions in hospitalized COVID-19 patients.
    Yang K; Zeng J; Dai W; Chen M; Yang F
    J Infect Dev Ctries; 2022 Sep; 16(9):1406-1412. PubMed ID: 36223614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lopinavir/Ritonavir for COVID-19: a Systematic Review and Meta-Analysis.
    Amani B; Khanijahani A; Amani B; Hashemi P
    J Pharm Pharm Sci; 2021; 24():246-257. PubMed ID: 34048671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential Treatment Options for COVID-19: A Comprehensive Review of Global Pharmacological Development Efforts.
    Neupane K; Ahmed Z; Pervez H; Ashraf R; Majeed A
    Cureus; 2020 Jun; 12(6):e8845. PubMed ID: 32754388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiviral Therapeutic Approaches for SARS-CoV-2 Infection: A Systematic Review.
    Gil Martínez V; Avedillo Salas A; Santander Ballestín S
    Pharmaceuticals (Basel); 2021 Jul; 14(8):. PubMed ID: 34451833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Agreement of treatment effects from observational studies and randomized controlled trials evaluating hydroxychloroquine, lopinavir-ritonavir, or dexamethasone for covid-19: meta-epidemiological study.
    Moneer O; Daly G; Skydel JJ; Nyhan K; Lurie P; Ross JS; Wallach JD
    BMJ; 2022 May; 377():e069400. PubMed ID: 35537738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of lopinavir/ritonavir and hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 at concentrations achievable by usual doses.
    Kang CK; Seong MW; Choi SJ; Kim TS; Choe PG; Song SH; Kim NJ; Park WB; Oh MD
    Korean J Intern Med; 2020 Jul; 35(4):782-787. PubMed ID: 32460458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the Current Therapeutic Approaches for COVID-19: A Systematic Review and a Meta-analysis.
    Abdelrahman Z; Liu Q; Jiang S; Li M; Sun Q; Zhang Y; Wang X
    Front Pharmacol; 2021; 12():607408. PubMed ID: 33790785
    [No Abstract]   [Full Text] [Related]  

  • 15. Major ongoing clinical trials for COVID-19 treatment and studies currently being conducted or scheduled in Japan.
    Ito K; Ohmagari N; Mikami A; Sugiura W
    Glob Health Med; 2020 Apr; 2(2):96-101. PubMed ID: 33330784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review.
    Vargas M; Servillo G; Einav S
    Eur Rev Med Pharmacol Sci; 2020 Aug; 24(16):8592-8605. PubMed ID: 32894567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Review of Treatment of Coronavirus Disease 2019 (COVID-19): Therapeutic Repurposing and Unmet Clinical Needs.
    Chen PL; Lee NY; Cia CT; Ko WC; Hsueh PR
    Front Pharmacol; 2020; 11():584956. PubMed ID: 33364959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials.
    Dijk SW; Krijkamp EM; Kunst N; Gross CP; Wong JB; Hunink MGM
    Value Health; 2022 Aug; 25(8):1268-1280. PubMed ID: 35490085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations.
    Marzolini C; Stader F; Stoeckle M; Franzeck F; Egli A; Bassetti S; Hollinger A; Osthoff M; Weisser M; Gebhard CE; Baettig V; Geenen J; Khanna N; Tschudin-Sutter S; Mueller D; Hirsch HH; Battegay M; Sendi P
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32641296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tocilizumab for treating severe COVID-19 pneumonia refractory to combined hydroxychloroquine, lopinavir plus ritonavir, and favipiravir: A case series.
    Surabotsophon M; Klai-On Y; Thanachartwet V; Khunapornphairote S; Chamnanchanunt S; Racharak T; Laisuan W; Sahassananda D; Hapunna S; Jinapuk S; Leelasetakul S; Desakorn V
    Clin Case Rep; 2020 Dec; 8(12):3264-3277. PubMed ID: 33230415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.